Member Info for LTbeliever

Which sell, NU? the 45 mln?
I think that was a BUY, it was early morning on the 7th and obviously it took the broker some time to execute;
I believe that this buyer had insider knowledge about the Update and this trade was a big reason for the day's big jump (on no news).
It's about 0.75% of the share capital so if it was a SELL, you wouldn't have such a jump. Plus, if it's an existing Holder, it may be announced as an RNS in a few days (if a threshold has been passed).

I reckon that, for 2022, the definite Revenue sources, even excluding completely the CR deal, BT approval and Skin tests, are:
1. PD sales - 5-6 million (min)
2. MW sales - another 5-6 million (min)
3. Labskin - 2-3 million?

So, easily 15 million minimum IMO.

Big unknown is Microtox PD sales in H2, once mass production starts; 200 units in month 1 @ what average price?
DVRG bought 3 units from MSYS for 33k (wholesale I guess, as retail is about 50k); would it be reasonable to say, 2k per unit?
There will probably be different sizes and prices, so 2k sounds reasonable IMO.
So, if sales rise every month (realistic), we are looking at maybe 3-4 million in H2 just from miniaturised PD sales.
Plus, the ongoing PD sales ot Government and Utilities of say, another 4-5 million?
Thus, 1/3 of 2022 Revenue (assuming 24 million) would come from PD sales alone.
DYOR

https://www.defensenews.com/land/2021/10/11/covid-snags-armys-race-to-fly-future-helicopter-with-next-gen-engine/

This is all I could find, from October 21 - talks about a Jan. 22 launch..."The first engine to test is now expected in January 2022, according to the Army’s Program Executive Office Aviation"

Would be nice to get some news in the next couple of weeks.

https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2021/11/20210928-TRT-Allenby-Capital-Finals.pdf?c2499=on

Let's get some news on ITEP soon, and from Bridgestone...still a long way from Allenby's target Price!

Wasn't the prototype supposed to be ready by End of 2021, as per TRT's Final Results in September?
..."GE's Improved Turbine Engine Program ("ITEP"), which is scheduled to execute the First Engine To Test (FETT) by the end of this calendar year"...anybody knows anything?

https://www.geaviation.com/military/engines/t901-turboshaft-engine

https://im-mining.com/2021/12/02/bridgestone-completes-acqusiution-mining-tyre-management-major-otraco-downer-edi/

NU,
You beat me to it :))
PIs have no chance BUT can at least buy and hold..Big Boys will follow.
Nobody was buying at 0.14 (almost nobody :) ) but at 0.19 Big Boys are happy to buy (at 40% higher, who's cleverer, the PI or the Big Boy?).

just released now...that would explain the big rise on Friday morning; either the guy had some inside info, or...?

At least, it wasn't a SELL!

Check the Notes in the Audited Fin. Statements.
From memory, some share options (1-2% of capital appx) are vesting next year for Employees and another 10% in Glenn/GJB's names in 2024.

Hopefully, the clearer 2022 path to near breakeven, and 2023 profitability will deter some wobbly TP clients from selling.

Thanks PC,
Although it offers nothing that we don't already know, at least they now cover MSYS so we should get hopefully some numbers later this year and more market visibility gradually.

308,
GJB was not so forthcoming about the reasons for the big delay of Microtox BT's launch; if you recall, he only mentioned that he expected approval - didn't specify by which authority - in H1 this year.
But we have had false dawns before so, don't hold your breath...especially if the regulators are dragging their feet for whatever reason.
I have more hopes for PD, which is more of a sure thing, as it has been tested already and by April it will be mass-produced at various sizes; this indicates that there are already many interested parties and hence, big orders to follow.

0.50 SP, my guess would be July the earliest...we need all 3 major drivers to come through - China, Bioprocessing deals and more water monitoring deals, via DVRG.
But, I really hope we get this SP much earlier.

I think this was to be expected, given the healthy rise from 0.14.
As I wrote on last Friday ..."Of course the MktMaker knows that there are news coming, maybe even aware of the exact RNS, especially if it's on Monday next; therefore, SP has been marked up either in anticipation of this.."
The important news today is that the Co has turned the corner and we should be looking forward to:
1. Significant rise in Turnover (I estimate 3-4x) Vs 2021
2. Getting nearer to Cash B/E and therefore, the rerating of the Co - from a potential dilution scenario - to a fast growing Co, whose products and services are price inelastic. IMO

Max19,
Cash was 6mln appx at Y/E2020. Cash now should be around 4mln.
I estimate that there was a cash inflow of appx 450k (from Gross Profit of 50% on 0.9mln), plus another 200-250k from R&D credits, minus 2.6-2.7 outflows.
I assume expenses are slightly reduced given the R&D synergies with DVRG at York, plus reduced travelling.
DYOR

Orders for the year have exceeded £1m
backlog of orders remaining from 2021 will be shipped in early FY22
2022 is about significant business inflection
commercial offering to support a number of new, high-value applications in major markets and geographies.
Company has continued its discussions with potential bioprocessing CRO partners, and with the alleviation of international travel, progress is anticipated to accelerate in FY22.
significantly expands the range of detectable compounds and fields of use for the Company's technology, with potential applications across therapeutics, antibiotics, pesticides, petrochemicals, and personal care products.
the Company's transition to workflow solution sales will establish higher-level end-user engagement.
Progress on this strategy has been made in 2021 contributing to the Company's order increase, particularly in H2 2021, and the Board believes this progress will yield significant gains in 2022.
Further progress is being made towards driving the value of data through collaborations on software and AI in Environmental Health....Potential markets span industries including Pharmaceuticals/Biopharmaceuticals, Food Safety, Environmental and Clinical, and this business will further augment the Company's ongoing transition towards offering complete solutions to end-users in Human and Environmental Health.
Outlook
The Company has entered 2022 with a healthy sales opportunities pipeline. The Board is targeting a significant increase in revenues in 2022, underpinned by scientific services opportunities, particularly in bioprocessing and water markets, but also the extension of Microsaic's detection platform into Human and Environmental Health real-time monitoring.

1 mln Sales for FY2021, as projected here on this BB, rising to 4-5 mln this year (half of it may come via DVRG - let's see their Revenue projections for 2022).
Looking forward to an exciting H1, with RNSs on
China,
Bioprocessing deals with big pharma,
conversion of Waste monitoring trials (with DVRG) to sales
and many other collaborations that we know nothing about right now!
GLA

PaulC,
Of course the MktMaker knows that there are news coming, maybe even aware of the exact RNS, especially if it's on Monday next; therefore, SP has been marked up either in anticipation of this, or just because there was a bit of a speculative frenzy.
The main risk Mkt has been worried about is another disappointment of low revenues and a cash raising; when this fear is out of the way (I reckon by Sept, when interims are released), the SP will definitely rerate, if not sooner.
DYOR

Over 70mln shares SOLD today;
No NEWS, pure speculative buying and selling;
but SP still UP 20%.
This indicates what the potential for GAINS is when REAL NEWS are released!
It seems that the tide is slowly but surely turning. The patient will be rewarded.
GLA